Literature DB >> 15928674

Tumour vascular targeting.

Dario Neri1, Roy Bicknell.   

Abstract

It is now accepted that the growth of solid tumours is dependent on their capacity to acquire a blood supply, and much effort has been directed towards the development of agents (known as anti-angiogenics) that disrupt this process. More recently, it has become apparent that targeted destruction of the established tumour vasculature is another avenue for exciting therapeutic opportunities. In this article, we present evidence that vascular targeting is an effective antitumour strategy in animal models, describe strategies for identifying putative tumour vascular targets and discuss future prospects for vascular targeting in the clinic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928674     DOI: 10.1038/nrc1627

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  160 in total

1.  Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery.

Authors:  Kerstin Galler; Kerstin Junker; Marcus Franz; Julia Hentschel; Petra Richter; Mieczyslaw Gajda; Angela Göhlert; Ferdinand von Eggeling; Regine Heller; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2011-11-11       Impact factor: 4.304

Review 2.  Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.

Authors:  L V Klotz; M E Eichhorn; B Schwarz; H Seeliger; M K Angele; K-W Jauch; Christiane J Bruns
Journal:  Langenbecks Arch Surg       Date:  2012-03-14       Impact factor: 3.445

Review 3.  Overcoming key technological challenges in using mass spectrometry for mapping cell surfaces in tissues.

Authors:  Noelle M Griffin; Jan E Schnitzer
Journal:  Mol Cell Proteomics       Date:  2010-06-14       Impact factor: 5.911

Review 4.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

5.  The cargo of CRPPR-conjugated liposomes crosses the intact murine cardiac endothelium.

Authors:  Hua Zhang; Ning Li; Padmini Sirish; Lisa Mahakian; Elizabeth Ingham; Fitz-Roy Curry; Soichiro Yamada; Nipavan Chiamvimonvat; Katherine W Ferrara
Journal:  J Control Release       Date:  2012-07-07       Impact factor: 9.776

6.  Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.

Authors:  Yushu Joy Xie; Michael Dougan; Noor Jailkhani; Jessica Ingram; Tao Fang; Laura Kummer; Noor Momin; Novalia Pishesha; Steffen Rickelt; Richard O Hynes; Hidde Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-01       Impact factor: 11.205

7.  Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes.

Authors:  Dandan Luo; Jumin Geng; Nasi Li; Kevin A Carter; Shuai Shao; G Ekin Atilla-Gokcumen; Jonathan F Lovell
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

8.  Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site.

Authors:  Thomas List; Dario Neri
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

9.  Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.

Authors:  Chunsheng Li; Ann-Marie Chacko; Jia Hu; Kosei Hasegawa; Jennifer Swails; Luigi Grasso; Wafik S El-Deiry; Nicholas Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  Cancer Biol Ther       Date:  2014-02-19       Impact factor: 4.742

10.  Fibronectin fibrillogenesis regulates three-dimensional neovessel formation.

Authors:  Xiaoming Zhou; R Grant Rowe; Nobuaki Hiraoka; Jerry P George; Denis Wirtz; Deane F Mosher; Ismo Virtanen; Michael A Chernousov; Stephen J Weiss
Journal:  Genes Dev       Date:  2008-05-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.